Several research endeavors have indicated the possible involvement of IL-4, IL-10, and IL-13 in mitigating the aggressive characteristics of cancer within bone structures, underscoring their viability as pharmacological targets for the management of bone metastases [26]. Here, IL4 is linked to cancer.